BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Antibody-Mediated Rejection readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Antibody-Mediated Rej
 ection\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06744647-11164@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Cevolisiran: Phase 2 readout est. (NCT06744647)
DESCRIPTION:Cevolisiran\, phase 2\, Antibody-Mediated Rejection.\nStudy: Ph
 ase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After
  Kidney Transplantation\nEstimated primary completion: 11 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cevolisiran#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06744647
URL:https://assetmemo.bio/drug/cevolisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
